Motif Bio plc (AIM: MTFB) (NASDAQ: MTFB) has received a Notice of Allowance from the US Patent and Trademark Office, the biopharmaceutical company revealed on Wednesday.
The two new patents relate to the use of iclaprim to treat patients with bacterial infections, including acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia and Staphylococcus aureus lung infections in patients with cystic fibrosis.
These patents give Motif Bio additional exclusivity for iclaprim in the treatment of bacterial infections through to November 2037.
Iclaprim is a novel investigational antibiotic with a targeted Gram-positive spectrum of activity. According to Motif Bio, in contrast to commonly used broad-spectrum antibiotics, this 'precision medicine' approach is consistent with antibiotic stewardship principles which, among other things, seek to reduce the inappropriate use of broad-spectrum products to avoid the build-up of resistance and to lessen the impact on the microbiome of the patient.
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial